PDS Biotech reports Q2 net loss $9.4M, clinical updates on PDS0101 and PDS01ADC

PDS Biotechnology Corp

2025-Q2 EPS reported -$0.41 vs consensus -$0.24 ▼ miss (-72.3%)

Net loss $9.4M ($0.21/dil share) vs $8.3M ($0.23) in Q2 2024.
R&D $4.2M, G&A $3.4M; total operating expenses $7.6M vs $8.7M.
Cash $31.9M (6/30/25) vs $41.7M (12/31/24); net interest expense $1.8M vs $0.5M.
Colorectal cancer cohort of Phase 2 trial with PDS01ADC met expansion criteria (≥6 of 9 objective responses).
Phase 3 VERSATILE-003 trial for PDS0101 in HPV16+ HNSCC progressing; 3 ASCO 2025 abstracts presented.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.